TheraRadar
← Back
Data updated: Jun 28, 2026

CENTRAL WELDING SUPPLY

Pharma
Pharmaceuticals

CENTRAL WELDING SUPPLY is a pharmaceutical company with 2 FDA-approved products.

2015
Since
2
Drugs
-
Trials
8
New Drugs (2yr)
Modality:
2 Small Molecules

CENTRAL WELDING SUPPLY's Key Drugs

CENTRAL WELDING SUPPLY's core commercial portfolio centers on MEDICAL AIR, USP, CARBON DIOXIDE, USP — its most strategically important drugs approved in the last 15 years.

MEDICAL AIR, USP
Respiratory
Approved 2013
CARBON DIOXIDE, USP
Respiratory
Approved 2013

CENTRAL WELDING SUPPLY's Recent FDA Approvals

CENTRAL WELDING SUPPLY secured 8 new FDA approvals for novel drugs (NDA/BLA) in the last two years.

MEDICAL AIR, USP NDA
2026-02-17
CARBON DIOXIDE, USP NDA
2025-10-25
carbon dioxide
CARBON DIOXIDE, USP NDA
2025-06-16
carbon dioxide
CARBON DIOXIDE, USP NDA
2025-04-21
carbon dioxide
Carbon Dioxide, USP NDA
2025-02-02
carbon dioxide
Carbon Dioxide, USP NDA
2024-11-09
carbon dioxide, usp
CARBON DIOXIDE, USP NDA
2024-08-10
carbon dioxide
MEDICAL AIR, USP NDA
2024-07-13
medical air

CENTRAL WELDING SUPPLY's Therapeutic Areas

Disease areas where CENTRAL WELDING SUPPLY has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.

No indication data

CENTRAL WELDING SUPPLY Pipeline Snapshot

Active clinical trials for CENTRAL WELDING SUPPLY across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • MEDICAL AIR, USP leads revenue
  • • 2 key drugs tracked

Trial Catalysts

  • • Active trial monitoring
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling